Cell Culture Industry Overview
The global cell culture media market size was estimated at USD 4.73 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 12.54% from 2024 to 2030.
Cell culture media is generally a gel or liquid including compounds required to regulate and support the growth of cells or microorganisms used in the manufacturing of biopharmaceuticals. Culture media is a critical ingredient in biopharmaceutical manufacturing, aiding the growth of cells, and is the fastest-growing segment within this market. This growth is mainly driven by growing demand for biopharmaceuticals, favorable governmental policies, and increasing investment in RD.
Gather more insights about the market drivers, restrains and growth of the Cell Culture Market
The outbreak of COVID-19 has improved demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, Vero cell line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium manufactured by Lonza Bioscience is a protein-free medium, of non-animal origin designed to support the growth of Vero cells and MDCK.
Furthermore, cell culture-produced AAV vectors have also gained thrust as one of the most effective protein and gene delivery tools in vaccine manufacturing as well as gene therapy. Key market players are expanding their production capabilities. In 2021, Sartorius increased its production in all regions due to elevated demand in its core business and to additional customer needs related to COVID-19 therapeutics and COVID-19 vaccines. The biosimilars market is on the cusp of momentous growth. This growth is due to several mAb biosimilars that are anticipated to be launched in a few years as patents on significant drugs, such as trastuzumab (Herceptin from Roche), infliximab (Remicade from JJ), and Adalimumab (Humira from Abbott) are going to expire.
Additionally, the FDA’s approval of cell-based candidate vaccine viruses (CVVs) for use in cell-based influenza vaccines could advance the efficiency of cell-based flu vaccines. Cell culture technology has been used to develop other U.S.-licensed vaccines, comprising vaccines for smallpox, rotavirus, rubella, hepatitis chickenpox, and polio. Furthermore, for 2021-2022 influenza season, all 4 flu viruses used in the cell-based vaccine are cell-derived. For instance, in October 2021, Seqirus received U.S. FDA approval for FLUCELVAX QUADRIVALENT, the first and the only cell-based influenza vaccine in the U.S.
Browse through Grand View Research's Biotechnology Industry Research Reports.
- The global biosimilars market size was valued at USD 21.8 billion in 2022 and is expected to grow at a compound annual growth rate(CAGR) of 15.9% over the forecast period.
- The global vaccine market size was estimated at USD 76.08 billion in 2023 and is expected to grow at a CAGR of 5.74% from 2024 to 2030.
Cell Culture Market Segmentation
Grand View Research has segmented the global cell culture media market on the basis of on product, application, type, end-use, and region:
Cell Culture Media Product Outlook (Revenue, USD Million, 2018 - 2030)
- Serum-free Media
- CHO Media
- BHK Medium
- Vero Medium
- HEK 293 Media
- Other Serum-free media
- Classical Media
- Stem Cell Culture Media
- Specialty Media
- Chemically Defined Media
- Other Cell Culture Media
Cell Culture Media Application Outlook (Revenue, USD Million, 2018 - 2030)
- Biopharmaceutical Production
- Monoclonal Antibodies
- Vaccines Production
- Other Therapeutic Proteins
- Diagnostics
- Drug Screening And Development
- Tissue Engineering And Regenerative Medicine
- Cell And Gene Therapy
- Other Tissue Engineering And Regenerative Medicine Applications
- Other Applications
Cell Culture Media Type Outlook (Revenue, USD Million, 2018 - 2030)
- Liquid Media
- Semi-solid And Solid Media
Cell Culture Media End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Pharmaceutical And Biotechnology Companies
- Hospitals And Diagnostic Laboratories
- Research And Academic Institutes
- Other End-users
Cell Culture Media Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Key Companies profiled:
- Sartorius AG
- Danaher
- Merck KGaA
- Thermo Fisher Scientific, Inc.
- FUJIFILM Corporation
- Lonza
- BD
- STEMCELL Technologies
- Cell Biologics, Inc.
- PromoCell GmbH
Key Cell Culture Company Insights
Key players in cell culture media market are implementing various strategies including partnership, merger and acquisition, geographical expansion, and strategic collaboration to expand their market presence. In July 2023, Merck KGaA invested USD 24.38 million to boost cell culture media production in the U.S. This development expanded the production capacity of the Lenexa facility to manufacture cell culture media.
In September 2023, Celltrion invested USD 94.5 million to construct a facility with an annual production capacity of 8 million vials in Songdo, Incheon. The new development is expected to increase the bioreactor capacity to 600,000 L and will be operational in 2027. In March 2023, Samsung Biologics announced that it would commence the construction of a fifth plant holding a capacity of 180,000 liters. Post completion, Samsung Biologics will maintain its global biomanufacturing capacity leadership with a total of 784,000 liters.
Order a free sample PDF of the Cell Culture Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
